Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each...
-
ALLSCHWIL/BASEL, SWITZERLAND - 23 January 2017 - Actelion Ltd (SIX: ATLN) today announced that the MAESTRO study to assess the efficacy, safety and tolerability of macitentan in patients with...
-
ALLSCHWIL/BASEL, SCHWEIZ - 23. Januar 2017 - Actelion Ltd (SIX: ATLN) gab heute bekannt, dass die MAESTRO-Studie zur Ermittlung der Wirksamkeit, Sicherheit und Verträglichkeit von Macitentan bei...
-
ALLSCHWIL, SWITZERLAND - 21 December 2016 - Actelion (SIX: ATLN) has entered into exclusive negotiations with Johnson & Johnson regarding a possible strategic transaction. There can be no...
-
ALLSCHWIL/BASEL, SWITZERLAND - 16 December 2016 - Actelion Ltd (SIX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European...
-
ALLSCHWIL/BASEL, SCHWEIZ - 16. Dezember 2016 - Actelion Ltd (SIX: ATLN) gab heute bekannt, dass das Committee for Medical Products for Human Use (CHMP), der wissenschaftliche Ausschuss der...
-
ALLSCHWIL, SWITZERLAND - 14 December 2016 - Actelion (SIX: ATLN) has taken note of the announcement by Johnson & Johnson (J&J) and confirms that J&J has withdrawn from the discussions....
-
ALLSCHWIL, SWITZERLAND - 25 November 2016 - Actelion (SIX: ATLN) confirmed today that it has been approached by Johnson & Johnson about a possible transaction. There can be no certainty that...
-
ALLSCHWIL/BASEL, SCHWEIZ - 07. November 2016 - Actelion Ltd (SIX: ATLN) kündigt für heute (Montag, 07. November, 14:00 Uhr MEZ) einen Webcast für Investoren an, in dessen Rahmen das Unternehmen ein...
-
ALLSCHWIL/BASEL, SWITZERLAND - 07 November 2016 - Actelion Ltd (SIX: ATLN) announced that the company will provide an update on its cardiovascular activities today (Monday, 07 November) in an...